Background: We projected cancer mortality statistics for 2018 for the European Union (EU) and its six more populous countries, using the most recent available data. We focused on colorectal cancer.
Introduction
Since 2011, we have published current year estimates for cancer mortality statistics based on recent data [1] [2] [3] . In this work, we present statistics for 2018 for the European Union (EU) and its six most populous countries, for the most common sites of cancer death plus all cancers combined. We also added bladder and ovarian cancer due to the high number of deaths in the EU [4, 5] . Since reports from outside the EU found increasing trends of colorectal cancer incidence/mortality below age 50 years, in contrast to the favourable trends at older ages [6] , a specific focus was devoted to analysing colorectal cancer mortality by age group.
(C33-C34), breast (C50), uterus (cervix and corpus) (C53-C55), ovary (C56), prostate (C61), bladder (C67), leukaemia (C91-C95), and total cancers (C00-D48).
We computed age-specific numbers of deaths and rates for 5-year age groups (0-4 to 85þ years) and calendar year or quinquennia. We used the direct method (world standard population) to calculate agestandardized rates.
We fitted a Poisson count data joinpoint regression model to the logarithm of each 5-year age-specific death number to identify the most recent trend segment [10] . The model was set to a maximum of six segments (five joinpoints) and to include at least five data points in the last segment. Agestandardized rates were also analysed with joinpoint regression models with up to four trend segments. We estimated predicted age-specific numbers of deaths and 95% prediction intervals (PIs) for 2018 by applying a linear model to the mortality data from each age group over the most recent trend segment identified by the joinpoint model. We used predicted agespecific numbers of deaths and the predicted population from Eurostat [8] to compute the predicted age-specific and age-standardized death rates (world population) with 95% PIs. Table 1 shows predicted cancer deaths and age-standardized rates with 95% PIs for 2018 for the studied neoplasms in the whole EU, and comparison data for 2012. In men, we predict 765 000 cancer deaths in 2018, and 617 000 in women, for a total of 1 382 000 deaths, compared with 1 333 362 in 2012, thus increasing by 3.6%. The predicted age-standardized rates for 2018 are 128.9/ 100 000 men and 83.6/100 000 women, compared with 143.8/ 100 000 men and 88.0/100 000 women in 2012, with falls of 10.3% in men and 5.0% in women. Figure 1 shows bar plots of age-standardized death rates per 100 000 population for all neoplasms and the 10 considered sites in 2012, and expected rates for 2018 in EU men and women, with 95% PIs. Lung cancer has the highest predicted rates in both sexes, 32.4/100 000 in men and 14.7 in women; however, we registered a 13.0% fall in men since 2012, and a 5.8% rise in women. Expected deaths in 2018 were 183 100 men and 94 500 women ($20% of total cancer deaths). Colorectal cancer accounts for the second highest number of deaths for 2018 with 177 400 deaths, with rates of 15.8/100 000 men and 9.2/100 000 women, declining since 2012 by 6.7% in men and 7.5% in women. Breast cancer has the second highest predicted rate in women, 13.7/100 000 (92 700 deaths), with a 9.5% decline since 2012. Prostate cancer has the third highest rate in men, 10.1/100 000, and declines by 8.5%. Pancreatic cancer shows stable rates in men, 7.9/100 000, but is unfavourable in women (5.6/100 000 in 2018, þ2.8%). Stomach cancer falls 19.0% in men and 17.1% in women. Uterine and ovarian cancers display similar behaviour, with predicted rates around 4.7/100 000, falls over 6%, and about 30 000 deaths. Bladder cancer rates are 5.1/ 100 000 in men (À4.0%; 34 700 deaths) and 1.1/100 000 in women (À5.0%; 11 100 deaths). Leukaemia represents 3% of total cancer deaths (14% fall since 2012). Figure 2 shows cancer mortality rates for EU men and women in quinquennia from 1970 to 2012, and predicted rates for 2018 with 95% PIs, for all neoplasms (left) and each cancer site for men (centre) and women (right). In men, the falling rates are mainly influenced by lung cancer, since the late 1980s, and stomach cancer, which declined over the whole period. In women the greatest falls were for breast, colorectal and stomach cancer, while lung cancer steadily increased. Pancreatic cancer shows a steady Tables S1-S9 and Figures S1 and S2, available at Annals of Oncology online). In general, they show earlier and larger declines in Western Europe, and a tendency towards a levelling of rates across the EU. Figure 1 . Bar-plots of age-standardized (world population) death rates per 100 000 persons for the year 2012 (dark grey, blue online) and predicted rates for 2018 (light grey, green online) with 95% prediction intervals (PIs) for total cancer and the ten major cancer sites in EU men and women. ASR, age-standardized mortality rates using the world standard population.
Results
Annals of Oncology Table 2 shows age-standardized mortality rates for colorectal cancer for the six countries in 2005-2009 and 2012, and the predicted rates for 2018 with 95% PIs. Rates for all ages and truncated for 30-49, 50-69, and 70þ years age groups for the EU are also presented. All trends were favourable. In men, France, Germany and the UK showed the greatest declines between 2012 and 2018 (14%), while Poland the lowest one. In women the greatest decline is registered for Germany and the lowest one in the UK. Figure 4 displays joinpoint analysis of colorectal cancer agestandardized mortality rates for the EU, in both sexes and different age groups, along with predictions for 2018 and 95% PIs. Except for age 30-49 years, male rates rose up to the mid-1990s, thereafter trends decrease appreciably. Women in all age groups and men aged 30-49 display steady downward patterns, with favourable predicted trends. Figure 5 shows the estimated number of avoided cancer deaths for the EU from 1989 (light grey area, green online) due to the declines in rates since 1990. We predict 392 000 avoided deaths in 2018 alone (275 000 men and 117 000 women) and a total of 4 930 000 (3 288 000 in men and 1 642 000 in women) over the whole period.
Discussion
The steady declines in overall cancer mortality rates in the EU in both sexes are predicted to continue up to 2018, with male rates falling 10.3% and 5.0% in women since 2012. Unlike the United States [11] , cancer death numbers are increasing slightly, mainly due to population aging. Mortality from major cancer sites is decreasing, including stomach, colorectum, bladder and leukaemia in both sexes, prostate and lung in men; and breast, uterus (cervix and corpus), and ovary in women. Conversely, lung cancer rates in women are increasing, and pancreas mortality rates are predicted to level off.
Interpretation of the prediction models' results needs caution. We updated aggregate mortality data for the EU, and minor inconsistencies with previous reports are likely. The temporal length of the projection is also relatively large at 6 years (2012-2018) and at the limit for short term model reliability. The large populations under analysis should protect from random variation, but very recent changes in trends, as well as cohort-like effects are difficult to detect for this model. In addition, predictions are less valid for rarer cancers, such as stomach [12] .
Colorectal cancer
In the EU, colorectal cancer mortality has been declining since 1993 in men, and over the whole period in women. However, individual countries followed different trajectories. In the early 1970s there was an over twofold variation between high and low rates. Rates progressively converged up to the early 2000s (12% variation in men and 16% in women). Thereafter trends diverged, particularly in men, with a reversal in country rankings Figure 4 . Annual colorectal cancer age-standardized (world population) death rates in the EU per 100 000 for all-ages, 30-49, 50-69, and 70þ years age groups from 1970 to 2012, the resulting joinpoint regression models, and predicted rates for the year 2018 with 95% PIs. On the left, men and women at all-ages (full squares and full circles, respectively) and at 30-49 years (empty squares and empty circles), on the right, men and women at 50-69 years (full squares and full circles), and at 70þ years (empty squares and empty circles).
compared with the 1970s. The convergence of rates has been attributed to homogenization of diet and lifestyles across the EU [4, 13] . Migrant studies showed that colorectal cancer mortality tends to change faster than for other cancers following lifestyle and diet modification [14] . The subsequent divergence is difficult to explain. Identified risk factors for colorectal cancer include alcohol and tobacco, obesity and diabetes, sedentariness, and unhealthy dietary patterns [15] . Oral contraceptive (OC) and hormone replacement therapy (HRT) use may have decreased risk in women, partly explaining sex differences. The increased use of aspirin, mainly for cardiovascular disease prevention, likely reduces colorectal cancer incidence [16] . Substantial progresses in management and treatment of colorectal cancer have taken place. Screening is very effective in reducing colorectal cancer mortality and incidence [17] .
Trends in risk factor exposure differed within Europe, with declines in tobacco and alcohol consumption in men and increased prevalence of obesity, diabetes and sedentariness in several countries. OC and, until the early 2000s, HRT use increased. Differential access to effective treatment across Europe can also play a role [18, 19] . Since the early 2000s several European countries have introduced organized screening above 50 years of age [20] , and differential implementation and uptake may influence recent trends.
Since the early 2000s, incidence and/or mortality trends in the United States, Canada, Australia and Norway have been decreasing above 50 years of age, but increasing below [6] . Increases in obesity, sedentariness and other unfavourable lifestyle habits, not counterbalanced by screening, may explain rises in early onset colorectal cancer. In the EU, mortality below age 50 years is not increasing, but rates levelled off since 2008 in both sexes.
Bladder cancer
There is an over fourfold difference between male and female bladder cancer mortality rates. More frequent exposure in men to the two major established risk factors [21, 22] , i.e. tobacco and occupational exposure to aromatic amines and other bladder carcinogens, can partly explain the wide gender gap. Bladder cancer incidence rates are highly influenced by changes in classification, coding, and registration, but these are unlikely to affect mortality rates and criteria for death certification did not change appreciably over the considered period [4] . Temporal trends in exposure to tobacco and occupational carcinogens can largely account for bladder cancer mortality trends in EU men. The role of other risk factors remains undefined [22] . There are similarities in mortality trends from lung and bladder cancers, confirming the important role played by tobacco in bladder cancer burden. Since 2008, however, trends have become less favourable in men, contrary to lung cancer. ; estimated numbers of total cancer deaths by applying 1988 age-specific peak mortality rate (dark grey line). During the 31 years period 4 930 000 cancer deaths have been avoided (3 288 000 in men and 1 642 000 in women). In 2018 alone are predicted to be avoided 275 000 in men and 117 000 in women, for a total of 392 000. ASR, age specific rate.
Since the late 1980s, ovarian cancer mortality has been falling in the EU, after earlier increases, and a further 6% fall is predicted between 2012 and 2018. Falls started earlier in the UK and Germany, who once had the highest rates, and only later into the 2000s in Poland. OC use decreases the risk of ovarian cancer, and its spread throughout Europe largely accounts for the favourable trends and the different timing of onset [5] . A detailed analysis [5] showed that falls were larger in young women, although in some countries, including the UK and Germany, earlier spread of OC use resulted in substantial declines in women aged 70-79 years. Reductions in HRT use, a risk factor for ovarian cancer, after unfavourable results [23] , may also have contributed. The role of other risk factors is difficult to evaluate, while improvements in management and therapy may have played a minor role, since European mean 5-year survival was low and no substantial gains were observed over time [24] .
Other cancer sites
Lung cancer mortality mainly reflects different past smoking patterns in the two sexes. Lung cancer is now the leading cause of cancer deaths in both sexes in the EU. In spite of decreases in men, the tobacco death toll remains huge, and abating tobacco consumption remains a priority.
The marked decreases in breast cancer and leukaemia mortality are largely due to progress in management and treatment [25, 26] .
Stomach cancer steadily declined since the 1970s, mostly because of reduced Helicobacter pylori infection and tobacco smoking, and improvements in food preservation and diet [27] .
The decrease in uterine cancer mortality is largely due to the decreased incidence of cancer of the cervix uteri, due to the spreading across Europe of effective screening [20] . 
